Effects of 4 weeks treatment with chlorpromazine and/or trihexyphenidyl on the pituitary-gonadal axis in male paranoid schizophrenics

  • Pantelis Rinieris
  • John Hatzimanolis
  • Manolis Markianos
  • Costas Stefanis


Serum prolactin (PRL), luteinizing hormone (LH) and testosterone (T) levels were estimated in a group of 30 male paranoid schizophrenics before and after 4 weeks treatment with chlorpromazine and/or trihexyphenidyl, and in a group of 14 healthy male individuals. After treatment with chlorpromazine (100 mg t.i.d., p. o.), 10 patients presented a significant increase in serum PRL values and a significant decrease in serum T values. A significant increase in serum PRL values was also found in 10 patients who were treated with chlorpromazine (100 mg t.i.d., p. o.) plus trihexyphenidyl (5 mg t.i.d., p. o.). No significant difference in any of the investigated endocrine parameters was detected in 10 patients after 4 weeks administration of trihexyphenidyl (5mg t.i.d., p.o.). Following chlorpromazine treatment with or without concomitant administration of trihexyphenidyl, 20 patients showed a significant increase in serum PRL levels and a significant decrease in serum LH and T levels.

Key words

Chlorpromazine Trihexyphenidyl Prolactin Luteinizing hormone Testosterone Paranoid schizophrenia 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Anden NE, Butcher SG, Corrodi H, Fuxe K, Ungerstedt U (1970) Receptor activity and turnover of dopamine and noradrenaline after neuroleptics. Eur J Pharmacol 11:303–314Google Scholar
  2. Anden NE, Corrodi H, Fuxe K (1972) Effect of neuroleptic drugs on central catecholamine turnover assessed using tyrosine- and dopamine-β-hydroxylase inhibitors. J Pharm Pharmacol 24:177–182Google Scholar
  3. Apter A, Dickerman Z, Gonen N, Assa S, Prager-Lewin R, Kaufman H, Tyano S, Laron Z (1983) Effect of chlorpromazine on hypothalamic-pituitary-gonadal function in 10 adolescent schizophrenic boys. Am J Psychiatry 140:1588–1591Google Scholar
  4. Benkert O, Klein HE, Hofschuster E, Seibold C (1981) Effect of the anticholinergic drug biperiden on pituitary hormones and cortisol. Psychoneuroendocrinology 6:231–238Google Scholar
  5. Brambilla F, Guerrini A, Guastalla A, Rovere C, Riggi F (1975) Neuroendocrine effects of haloperidol therapy in chronic schizophrenia. Psychopharmacologia 44:17–22Google Scholar
  6. Cass Terry L, Crowley WR, Lynch C, Longserre C, Johnson MD (1982) Role of central epinephrine in regulation of anterior pituitary hormone secretion. Peptides 3:311–318Google Scholar
  7. Collu R, Jéquier JC, Leboeuf G, Letarte J, Ducharme JR (1975) Endocrine effects of pimozide, a specific dopaminergic blocker. J Clin Endocrinol Metab 41:981–984Google Scholar
  8. Davis BM, Brown GM, Miller M, Friesen HG, Kastin AJ, Davis KL (1982) Effects of cholinergic stimulation on pituitary hormone release. Psychoneuroendocrinology 7:347–354Google Scholar
  9. Davis JM, Vogel C, Gibbons R, Pavkovic I, Zhang M (1984) Pharmacoendocrinology of schizophrenia. In: Brown GM, Koslow SH, Reichlin S (eds) Neuroendocrinology and psychiatric disorder. Raven, New York, pp 29–53Google Scholar
  10. DeRivera JL, Lal S, Ettigi P, Hontella S, Muller HF, Friesen HG (1976) Effect of acute and chronic neuroleptic therapy on serum prolactin levels in men and women of different age groups. Clin Endocrinol 5:273–282Google Scholar
  11. Drouva SV, Gallo RV (1976) Catecholamine involvement in episodic luteinizing hormone release in adult ovariectomized rats. Endocrinology 99:651–658Google Scholar
  12. Halbreich U, Sachar EJ, Nathan RS, Asnis GM, Halpern FS (1980) The effect of benztropine mesylate on the prolactin response to haloperidol. Psychopharmacology 72:61–65Google Scholar
  13. Hanlon TE, Schoenrich C, Freinek W, Turek I, Kurland AA (1966) Perphenazine-benztropine mesylate treatment of newly admitted psychiatric patients. Psychopharmacologia 9:328–339Google Scholar
  14. Kolakowska T, Wiles DH, Gelder MG, McNeilly AS (1976) Clinical significance of plasma chlorpromazine levels. Psychopharmacology 49:101–107Google Scholar
  15. Krawiecka M, Goldberg D, Vaughan M (1977) A standardized psychiatric assessment scale for rating chronic psychotic patients. Acta Psychiatr Scand 55:299–308Google Scholar
  16. Krulich L (1979) Central neurotransmitters and the secretion of prolactin, GH, LH and TSH. Annu Rev Physiol 41:603–615Google Scholar
  17. Lal S, Mendis T, Cervantes P, Guyda H, DeRivera JL (1979) Effect of benztropine on haloperidol-induced prolactin secretion. Neuropsychobiology 5:327–331Google Scholar
  18. Martin JB, Reichlin S, Brown GM (1977) Neuroendocrinology of reproduction. In: Martin JB, Reichlin S, Brown GM (eds) Clinical neuroendocrinology. Davis, Philadelphia, pp 93–128Google Scholar
  19. Martin-DuPan R, Baumann P, Magrini G, Felber JP (1979) Neuroendocrine effects of chronic neuroleptic therapy in male psychiatric patients. Psychoneuroendocrinology 3:245–252Google Scholar
  20. Meltzer HY (1984) Neuroendocrine abnormalities in schizophrenia: prolactin, growth hormone, and gonadotrophins. In: Brown GM, Koslow SH, Reichlin S (eds) Neuroendocrinology and psychiatric disorder. Raven, New York, pp 1–28Google Scholar
  21. Nakagawa K, Obara T, Matsubara M, Kubo M (1982) Relationship of changes in serum concentrations of prolactin and testosterone during dopaminergic modulation in males. Clin Endocrinol 17:345–352Google Scholar
  22. Nathan RS, Asnis GM, Dyrenfurth I, Halpern FS, Halbreich U, Ostrow LC, Sachar EJ (1980) Plasma prolactin and testosterone during penfluridol treatment. Lancet II:94Google Scholar
  23. Praag HM van, Korf J (1975) Biochemical research into psychosis. Acta Psychiatr Scand 51:268–284Google Scholar
  24. Rivera-Calimlim L, Castaneda L, Lasagna L (1973) Effects of mode of management on plasma chlorpromazine in psychiatric patients. Clin Pharmacol Ther 14:978–986Google Scholar
  25. Rubin RT, Hays SE (1980) The prolactin secretory response to neuroleptic drugs: mechanisms, applications and limitations. Psychoneuroendocrinology 5:121–137Google Scholar
  26. Rubinstein L, Sawyer CH (1970) Role of catecholamines in stimulating the release of pituitary ovulating hormones in rats. Endocrinology 86:988–995Google Scholar
  27. Singh MM, Kay SR (1979) Therapeutic antagonism between anticholinergic antiparkinsonism agents and neuroleptics in schizophrenia. Neuropsychobiology 5:74–86Google Scholar
  28. Siris SG, Siris ES, Kammen DP van, Docherty JP, Alexander PE, Bunney WE (1980) Effects of dopamine blockade on gonadotropins and testosterone in men. Am J Psychiatry 137:211–214Google Scholar
  29. Wode-Helgodt B, Eneroth P, Fyrö B, Gullberg B, Sedvall G (1977) Effect of chlorpromazine treatment on prolactin levels in cerebrospinal fluid and plasma of psychotic patients. Acta Psychiatr Scand 56:280–293Google Scholar

Copyright information

© Springer-Verlag 1988

Authors and Affiliations

  • Pantelis Rinieris
    • 1
  • John Hatzimanolis
    • 1
  • Manolis Markianos
    • 1
  • Costas Stefanis
    • 1
  1. 1.Department of PsychiatryAthens University Medical School, Eginition HospitalAthensGreece

Personalised recommendations